Bacterial cupredoxin azurin and its interactions with the tumor suppressor protein p53

Biochemical and Biophysical Research Communications

Volumn 312, Issue 1, 2003, Pages 109-114

  Punj, Vasu ^a   Das Gupta, Tapas K ^a   Chakrabarty, Ananda M ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZURIN; BACTERIAL PROTEIN; CUPREDOXIN AZURIN; CYTOCHROME; DESOXYEPOTHILONE B; EPOTHILONE B; EPOTHILONE DERIVATIVE; FLUCYTOSINE; FLUOROURACIL; PACLITAXEL; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; BACTERIUM; CANCER; CANCER THERAPY; CONJUGATION; DRUG FORMULATION; HUMAN; MAMMAL CELL; MEDICAL RESEARCH; MICROORGANISM; MYCOBACTERIUM; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIDE EFFECT;

BACTERIA (MICROORGANISMS); MAMMALIA; MYCOBACTERIUM;

EID: 0345689559     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.09.217     Document Type: Article

References (27)

1. Chakrabarty A.M. Plasmids and nutritional diversity. Ornston L.N., Sligar S.G. Experiences in Biochemical Perception. 1982;111-120 Academic Press, New York.
2. Chakrabarty A.M. Moving ahead with pseudomonad genes. Atlas R.M. Many Faces, Many Microbes. 2000;235-242 ASM Press, Washington, DC.
3. Chakrabarty A.M. Diamond v. Chakrabarty: a historical perspective. Chisum D.S., Nard C.A., Schwartz H.F., Newman P., Kieff F.S. Principles of Patent Law. 1998;783-788 Foundation Press, New York.
4. Chakrabarty A.M. Patenting of life forms: from a concept to reality. Magnus D., Caplan A., McGee G. Who Owns Life? 2000;17-24 Prometheus Books, Amherst, NY.
5. Zaborina O., Misra N., Kostal J., Kamath S., Kapatral V., El-Azami El-Idrissi M., Prabhakar B.S., Chakrabarty A.M. P2Z-independent and P2Z receptor-mediated macrophage killing by Pseudomonas aeruginosa isolated from cystic fibrosis patients. Infect. Immun. 67:1999;5231-5242.
6. Zaborina O., Dhiman N., Chen M.L., Kostal J., Holder I.A., Chakrabarty A.M. Secreted products of a nonmucoid Pseudomonas aeruginosa strain induce two modes of macrophage killing: external-ATP-dependent, P2Z-receptor-mediated necrosis and ATP-independent caspase-mediated apoptosis. Microbiology. 146:2000;2521-2530.
7. Adrian C., Martin S.J. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem. Sci. 26:2001;390-397.
8. Yamada T., Goto M., Punj V., Zaborina O., Kimbara K., Das Gupta T.K., Chakrabarty A.M. The bacterial redox protein azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppressor protein p53. Infect. Immun. 70:2002;7054-7062.
9. Oren M. Decision making by p53: life, death and cancer. Cell Death Different. 10:2003;431-442.
10. De Rienzo F., Gabdoulline R.R., Menziani M.C., Wade R.C. Blue copper proteins: a comparative analysis of their molecular interaction properties. Protein Sci. 9:2000;1439-1454.
11. Goto M., Yamada T., Kimbara K., Horner J., Newcomb M., Das Gupta T.K., Chakrabarty A.M. Induction of apoptosis in macrophages by Pseudomonas aeruginosa azurin: tumor suppressor protein p53 and reactive oxygen species, but not redox activity, as critical elements in cytotoxicity. Mol. Microbiol. 47:2003;549-559.
12. Punj V., Chakrabarty A.M. Redox proteins in mammalian cell death: an evolutionarily conserved function in mitochondria and prokaryotes. Cell. Microbiol. 5:2003;225-231.
13. Ralph P., Nakoinz I. Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line. Nature. 257:1975;393-394.
14. Yamada T., Goto M., Punj V., Zaborina O., Chen M.L., Kimbara K., Majumdar D., Cunningham E., Das Gupta T.K., Chakrabarty A.M. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. USA. 99:2002;14098-14103.
15. Chakrabarty A.M. Microorganisms and cancer: quest for a therapy. J. Bacteriol. 185:2003;2683-2686.
16. Sznol M., Lin S.L., Bermudes D., Zheng L.-M., King I. Use of preferentially-replicating bacteria for the treatment of cancer. J. Clin. Invest. 105:2000;1027-1030.
17. Dang L.H., Bettegowda C., Huso D.L., Kinzler K.W., Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA. 98:2001;15155-15160.
18. Alexandroff A.D., Jackson A.M., O'Donnell M.A., James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 353:1999;1689-1694.
19. Hunter C.A., Yu D., Gee M., Ngo C.V., Sevignani C., Goldschmidt M., Golovkina T.V., Evans S., Lee W.F., Thomas-Tikhonenko A. Systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J. Immunol. 166:2001;5878-5881.
20. Altman K.-H., Wartmann M., O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta. 1470:2000;M79-M91.
21. Chou T.-C., Zhang X.-G., Balog A., Su D., Meng D., Savin K., Bertino J.R., Danishefsky S.J. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothiloneB. Proc. Natl. Acad. Sci. USA. 95:1998;9642-9647.
22. Liu G., Schwartz J.A., Brooks S.C. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res. 60:2000;1810-1814.
23. Prives C., Hall P.A. The p53 pathway. J. Pathol. 187:1999;112-126.
24. Anwar A., Dehn D., Siegel D., Kepa J.K., Tang L.J., Pietenpol J.A., Ross D. Interaction of human NAD(P)H:Quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J. Biol. Chem. 278:2003;10368-10373.
25. Wesierska-Gadek J., Wojciechowski J., Schmid G. Central and carboxy-terminal regions of human p53 protein are essential for interaction and complex formation with PARP-1. J. Cell. Biochem. 89:2003;220-232.
26. Majumder M., Ghosh A.K., Steele R., Ray R., Ray R.B. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J. Virol. 75:2001;1401-1407.
27. MacLachlan T.K., Takimoto R., El-Deiry W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol. 22:2002;4280-4292.